Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07396597

Physical Impairments in Premature Ventricular Complex

Premature ventricular complexes may be observed in individuals without underlying disease due to factors such as physical inactivity, advanced age, smoking, male sex, and psychosocial disturbances, and in some cases may result in sudden cardiac death. Therefore, the aim of this study is to investigate respiratory function, respiratory muscle strength, cough strength, handgrip strength, physical activity level, and quality of life in individuals with premature ventricular complexes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Izmir Democracy University

Izmir, 35140, Turkey (Türkiye)

Location contact

ESRA SUDE AKIN

CONTACT

GÜLŞAH BARĞI

CONTACT

0232 299 0739

About this study

The primary aim of this study is to comprehensively investigate respiratory function, respiratory muscle strength, cough strength, handgrip strength, physical activity level, and quality of life in individuals with premature ventricular complexes. Additionally, an important secondary aim is to identify potential differences in these parameters between individuals with premature ventricular complexes and healthy controls and to contribute original findings to the existing literature.Participants will be evaluated in terms of these parameters through clinical assessments, questionnaires, and measurements.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for Individuals with Premature Ventricular Complexes (PVCs):

  • Aged between 18 and 80 years
  • Presence of symptomatic premature ventricular complexes resistant to ≥1 antiarrhythmic medication (including β-blockers and calcium channel blockers)
  • Premature ventricular complex burden ≥10%
  • Ventricular arrhythmias originating from any focus within the right or left ventricle
  • Physically able to participate in all study assessments
  • Willingness to participate in the study by providing written informed consent

Inclusion criteria

for Control Group Participants:

  • Aged between 18 and 80 years
  • Healthy individuals
  • Willingness to participate in the study
  • Physically able to participate in all study assessments

Exclusion criteria

for Individuals with Premature Ventricular Complexes (PVCs):

  • Left ventricular ejection fraction (LVEF) <45% unless PVC-induced cardiomyopathy is documented (defined as a >15% improvement in LVEF following reduction of PVC burden through pharmacological therapy or ablation)
  • Progressive decline in LVEF within the last 4 months, regardless of etiology
  • Severe heart failure classified as New York Heart Association (NYHA) Class ≥III
  • Ventricular arrhythmias attributed to underlying structural heart disease, known myocardial scar, or myocarditis
  • Change in the dosage of antiarrhythmic medications (including β-blockers and calcium channel blockers) within 2 months prior to enrollment
  • Failed catheter ablation within 3 months prior to enrollment
  • Known thyroid disorders or individuals undergoing renal dialysis
  • Life expectancy <12 months
  • Presence of angina pectoris
  • Diagnosis of chronic obstructive pulmonary disease (COPD) or asthma
  • Resting heart rate >120 beats/min
  • Resting systolic blood pressure ≥180 mmHg
  • Resting diastolic blood pressure ≥100 mmHg
  • Resting peripheral oxygen saturation ≤90%

Exclusion criteria

for Control Group Participants:

  • Presence of premature ventricular complexes
  • Presence of any acute or chronic medical condition

Treatment and study plan

Physical Evaluations of Patients with Premature Ventricular Complex

Other

In this study, data from individuals with premature ventricular complex will be collected through face-to-face assessments. Respiratory functions, respiratory and peripheral muscle strength, cough strength, physical activity level, and quality of life will be assessed in these individuals who meet the inclusion criteria. All data obtained through these assessments will be collected from participants face-to-face at one time and for a maximum of approximately 1 hour.

Physical Evaluations of Healthy Individuals

Other

In this study, data from healthy individuals will be collected through face-to-face assessments. Respiratory functions, respiratory and peripheral muscle strength, cough strength, physical activity level, and quality of life will be assessed in these individuals who meet the inclusion criteria.All data obtained through these assessments will be collected from participants face-to-face at one time and for a maximum of approximately 1 hour.

Primary outcomes

  1. Maximal inspiratory pressure (MIP)

    Time frame: through study completion, an average of 1 year

    The MIP which shows respiratory muscle strength will be evaluated using a portable mouth pressure measuring device based on American Thoracic Society and European Respiratory Society criteria.

Secondary outcomes

  1. Maximal expiratory pressure (MEP)

    Time frame: through study completion, an average of 1 year

    The MEP which shows respiratory muscle strength will be evaluated using a portable mouth pressure measuring device based on American Thoracic Society and European Respiratory Society criteria.

  2. Forced vital capacity (FVC)

    Time frame: through study completion, an average of 1 year

    Pulmonary function (Forced vital capacity (FVC)) will be evaluated with a spirometer.

  3. Forced expiratory volume in the first second (FEV1)

    Time frame: through study completion, an average of 1 year

    Pulmonary function (Forced expiratory volume in the first second (FEV1)) will be evaluated with a spirometer.

  4. FEV1 / FVC

    Time frame: through study completion, an average of 1 year

    Pulmonary function (Forced expiratory volume in the first second/Forced vital capacity (FEV1 / FVC)) will be evaluated with a spirometer.

  5. Peak flow rate (PEF)

    Time frame: through study completion, an average of 1 year

    Pulmonary function (Peak flow rate (PEF)) will be evaluated with a spirometer.

  6. Cough Strength

    Time frame: through study completion, an average of 1 year

    Participants' peak cough expiratory flow (PCEF) values will be assessed in an upright sitting position using a peak cough flow meter (ExpiRite Peak Flow Meter, China). Following a deep inspiration, participants will be instructed to cough as forcefully as possible into the device. The best value obtained from at least three trials will be recorded.

  7. Handgrip Strength

    Time frame: through study completion, an average of 1 year

    Maximum isometric strength of the hand and forearm muscles will be measured using a hydraulic hand dynamometer.Measurements will be performed in an upright sitting position in accordance with guidelines. The mean of the three measurements for the right and left hands will be used for analysis.

  8. Assessment of Physical Activity

    Time frame: through study completion, an average of 1 year

    Participants' physical activity levels over the previous seven days will be assessed using the International Physical Activity Questionnaire-Short Form. The questionnaire consists of 7 items that assess time spent walking, and moderate- and vigorous-intensity physical activities over the last seven days. Total physical activity scores will be calculated by summing the duration (minutes) and frequency (days) of walking, moderate-intensity, and vigorous-intensity activities. Total physical activity score will be expressed as metabolic equivalent task minutes per week (MET-min/week).

  9. Assessment of Quality of Life

    Time frame: through study completion, an average of 1 year

    Participants' quality of life will be evaluated using the Short Form-36 Health Survey (SF-36). The SF-36 assesses eight health domains: general health, physical functioning, role limitations due to physical problems, role limitations due to emotional problems, social functioning, bodily pain, vitality, and mental health, along with one additional item assessing health transition. Participants will be instructed to respond to each question in a manner that best reflects their current condition, and researchers will provide clarifying guidance when necessary.

Study contacts

Contact information is provided by the study sponsor or research team.

ESRA SUDE AKIN

CONTACT

+90 232 299 0739

GÜLŞAH BARĞI

CONTACT

[email protected]

+90 232 299 0739

Sponsors and collaborators

Lead sponsor

Izmir Democracy University

Other

Registry information

Official study title

Investigation of Respiratory Functions, Muscle Strength, Physical Activity Level, and Quality of Life in Individuals With Premature Ventricular Complexes

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 9, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.